Kamal K. Abbi
Expertise in
26
conditions

Dr. Kamal K. Abbi

Oncology
Ascension Calumet Hospital - Cancer Care
614 Memorial Dr, 
Chilton, WI 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Expertise in
26
conditions
Ascension Calumet Hospital - Cancer Care
614 Memorial Dr, 
Chilton, WI 

Overview

Kamal K. Abbi, MD, is a board-certified, independent oncologist at Ascension Wisconsin in Chilton, Oshkosh, and Appleton near Green Bay, Wisconsin. Dr. Abbi diagnoses and treats cancer using medications, such as chemotherapy, immunotherapy and targeted therapies. Every appointment with Dr. Abbi starts with a conversation. He takes the time to answer all your questions - big and small.

Dr. Abbi is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Lymphofollicular Hyperplasia, Acute Monoblastic Leukemia (AmoL), Large-Cell Immunoblastic Lymphoma, and Bone Marrow Aspiration.

Dr. Abbi is board certified in The American Board Of Internal Medicine - Medical Oncology, American Board Of Internal Medicine, and The American Board Of Internal Medicine - Internal Medicine. He is actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 26 clinical trials. Dr. Abbi is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in WI

Board Certifications

The American Board Of Internal Medicine - Medical Oncology
American Board Of Internal Medicine
The American Board Of Internal Medicine - Internal Medicine

Fellowships

Memorial Sloan Kettering Cancer Center
The University of Toledo

Hospital Affiliations

Ascension Ne Wisconsin - St Elizabeth Campus
Osf St Francis Hospital And Medical Group
Schoolcraft Memorial Hospital
Ascension Calumet Hospital
Ascension NE Wisconsin - Mercy Campus
Ascension NE Wisconsin - St. Elizabeth Campus

Languages Spoken

English
Hindi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Children's Community Health
  • EPO
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Ascension Calumet Hospital - Cancer Care
614 Memorial Dr, Chilton, WI 53014
Other Locations
Ascension NE Wisconsin - St. Elizabeth Cancer Center
1506 S Oneida St, Appleton, WI 54915

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Procedure, Other
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
View 8 Less Clinical Trials

12 Total Publications

Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34+ selected graft.
Favorable long-term outcomes of hematopoietic stem cell transplantation for CMML with myeloablative conditioning, anti-thymocyte globulin, and CD34+ selected graft.
Journal: Bone marrow transplantation
Published: July 26, 2019
Similar Doctors
Expertise in
28
conditions
Dr. Zahid N. Dar
Hematology | Oncology
Expertise in
28
conditions
Dr. Zahid N. Dar
Hematology | Oncology
Referral may be required
Before you request

Vince Lombardi Cancer Clinic

855 N Westhaven Dr, 
Oshkosh, WI 
 (21.8 miles away)
920-456-7870
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Zahid Dar is a Hematologist and an Oncologist practicing medicine in Oshkosh, Wisconsin. Dr. Dar is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Metastatic Pleural Tumor, Paget Disease of the Breast, Familial Pancreatic Cancer, and Pleuropulmonary Blastoma. Dr. Dar is board certified in American Board Of Internal Medicine, Medical Oncology. Dr. Dar is currently accepting new patients.

Expertise in
50
conditions
Dr. Michael P. Mullane
Hematology | Oncology
Expertise in
50
conditions
Dr. Michael P. Mullane
Hematology | Oncology
Referral may be required
Before you request

Aurora BayCare Medical Center

2845 Greenbrier Rd, 
Green Bay, WI 
 (32.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Mullane is a Hematologist and an Oncologist practicing medicine in Green Bay, Wisconsin. Dr. Mullane is highly rated in 50 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Cancer, Pleuropulmonary Blastoma, and Monoclonal Gammopathy of Undetermined Significance (MGUS). Dr. Mullane is board certified in American Board Of Internal Medicine, Hematology. Dr. Mullane is currently accepting new patients.

Expertise in
18
conditions
Dr. Tracy J. Miles
Oncology | Hematology
Expertise in
18
conditions
Dr. Tracy J. Miles
Oncology | Hematology
Referral may be required

ThedaCare Cancer CareNeenah

130 Second Street, 
Neenah, WI 
 (18.7 miles away)
920-364-3600
Languages Spoken:
English, American Sign Language
See accepted insurances
Accepting New Patients

I believe in treating patients with the same care and respect that I would offer my family members. I recognize the unique challenges and needs each patient faces.What I like most about my job is interacting with patients and their family members. I have a passion for building relationships, providing support, empowering patients, continuous learning and making a meaningful difference in the lives of others.I chose to work in oncology because I enjoy providing both medical expertise and emotional support. I enjoy being there for my patients during challenging times, offering comfort, reassurance and guidance. Dr. Miles is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Paget Disease of the Breast, and Breast Cancer. Dr. Miles is board certified in Medical Oncology, American Board Of Internal Medicine (2013) and Internal Medicine, American Board Of Internal Medicine (2007). Dr. Miles is currently accepting new patients.

Frequently Asked Questions about Dr. Kamal K. Abbi

How do I make an appointment with Dr. Kamal K. Abbi?

You can book an appointment with Dr. Kamal K. Abbi by calling their office at 920-831-8900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kamal K. Abbi a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kamal K. Abbi is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kamal K. Abbi specialize in?

While Dr. Kamal K. Abbi is a Oncology, they have specific expertise in Lung Cancer, Lymphofollicular Hyperplasia, and Acute Monoblastic Leukemia (AmoL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Kamal K. Abbi participate in research or clinical trials?

Yes. Dr. Kamal K. Abbi has published 12 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Kamal K. Abbi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kamal K. Abbi accept my insurance?

Dr. Kamal K. Abbi accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 920-831-8900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Abbi's expertise for a condition
ConditionClose
    View All 22 Advanced Conditions
    View All 108 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile